Cardica faces possible NASDAQ delisting

Redwood City, CA-based Cardica (NASDAQ: CRDC) faces possible NASDAQ delisting because it doesn't meet the $50 million minimum market value.

The company received received a letter from the NASDAQ stock market June 21, according to an SEC filing. The company has the standard six-month grace period--until Dec. 20--to regain compliance. If at anytime during this grace period Cardica's market value of listed securities closes at $50 million or more for a minimum of 10 consecutive business days, NASDAQ will provide the company with confirmation of compliance, and the matter will be closed.

Cardica designs and manufactures proprietary stapling devices for surgical procedures, according to the company website. Its stapling technology is designed to minimize operating time and to enable minimally-invasive and robot-assisted surgeries.

Cardica stock closed Friday at $1.66, down a penny, the San Francisco Business Times notes.

- read the SEC filing
- get more from the San Francisco Business Times

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.